Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Cell Reports
|
February 22, 2023
Cofilin promotes tau pathology in Alzheimer's disease
Mingmin Yan, Li Tang, Lijun Dai, et al.
Frontiers in Oncology
|
March 21, 2020
Is Hydrogen Sulfide a Concern During Treatment of Lung Adenocarcinoma With Ammonium Tetrathiomolybdate?
Xiang Li, Na Li, Li Huang, et al.
Aging Cell
|
November 28, 2022
N-homocysteinylation of α-synuclein promotes its aggregation and neurotoxicity
Lingyan Zhou, Tao Guo, Lanxia Meng, et al.
Immunological Investigations
|
October 29, 2009
Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study
Stephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Immunological Investigations
|
July 27, 2010
Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study
Stephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Leukemia & Lymphoma
|
June 22, 2022
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study
Xiang Zhang, Yuqing Tu, Juan Shen, et al.
Circulation Research
|
July 9, 2005
Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide
Himanshu Gupta, Lijun Dai, Geeta Datta, et al.
Chemosphere
|
September 10, 2022
Exposure to the environmentally toxic pesticide maneb induces Parkinson's disease-like neurotoxicity in mice: A combined proteomic and metabolomic analysis
Chaoyang Liu, Zehua Liu, Yanyan Fang, et al.
Cell Death and Differentiation
|
August 22, 2024
The PM20D1-NADA pathway protects against Parkinson's disease
Yunying Yang, Sichun Chen, Li Zhang, et al.
Blood
|
March 28, 2012
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Suzanne Lentzsch, Amy O'Sullivan, Ryan C Kennedy, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Cell Reports
|
February 22, 2023
Cofilin promotes tau pathology in Alzheimer's disease
Mingmin Yan, Li Tang, Lijun Dai, et al.
Frontiers in Oncology
|
March 21, 2020
Is Hydrogen Sulfide a Concern During Treatment of Lung Adenocarcinoma With Ammonium Tetrathiomolybdate?
Xiang Li, Na Li, Li Huang, et al.
Aging Cell
|
November 28, 2022
N-homocysteinylation of α-synuclein promotes its aggregation and neurotoxicity
Lingyan Zhou, Tao Guo, Lanxia Meng, et al.
Immunological Investigations
|
October 29, 2009
Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study
Stephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Immunological Investigations
|
July 27, 2010
Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study
Stephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Leukemia & Lymphoma
|
June 22, 2022
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study
Xiang Zhang, Yuqing Tu, Juan Shen, et al.
Circulation Research
|
July 9, 2005
Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide
Himanshu Gupta, Lijun Dai, Geeta Datta, et al.
Chemosphere
|
September 10, 2022
Exposure to the environmentally toxic pesticide maneb induces Parkinson's disease-like neurotoxicity in mice: A combined proteomic and metabolomic analysis
Chaoyang Liu, Zehua Liu, Yanyan Fang, et al.
Cell Death and Differentiation
|
August 22, 2024
The PM20D1-NADA pathway protects against Parkinson's disease
Yunying Yang, Sichun Chen, Li Zhang, et al.
Blood
|
March 28, 2012
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Suzanne Lentzsch, Amy O'Sullivan, Ryan C Kennedy, et al.
Page
of 8